BEAM THERAPEUTICS INC. - COMMON STOCK

Beam Therapeutics Announces Pricing of Underwritten Offering

10 Mar 2025 06:01:26 By Nasdaq GlobeNewswire

Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation

10 Mar 2025 06:00:00 By Nasdaq GlobeNewswire

Beam Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Reiterates Anticipated Catalysts

25 Feb 2025 07:00:00 By Nasdaq GlobeNewswire

Beam Therapeutics to Participate in Upcoming March 2025 Investor Conferences

24 Feb 2025 07:00:00 By Nasdaq GlobeNewswire

Beam Therapeutics to Participate in Guggenheim SMID Cap Biotech Conference

30 Jan 2025 07:00:00 By Nasdaq GlobeNewswire

Beam Therapeutics to Encore Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at 2025 Tandem Meetings of ASTCT and CIBMTR

23 Jan 2025 07:00:00 By Nasdaq GlobeNewswire

Beam Therapeutics Announces Progress in Hematology and Genetic Disease Franchises and Outlines Key 2025 Anticipated Catalysts

13 Jan 2025 07:00:00 By Nasdaq GlobeNewswire

Beam Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

17 Dec 2024 07:00:00 By Nasdaq GlobeNewswire

Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting

08 Dec 2024 13:45:00 By Nasdaq GlobeNewswire

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting

07 Dec 2024 11:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer

06 Dec 2024 07:00:00 By Nasdaq GlobeNewswire

Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader

04 Dec 2024 07:00:00 By Nasdaq GlobeNewswire

Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference

12 Nov 2024 16:01:00 By Nasdaq GlobeNewswire

Beam Therapeutics to Present Data Across Hematology Franchise, Including First Clinical Data for BEAM-101 in Sickle Cell Disease and ESCAPE Non-human Primate Data, at American Society of Hematology (ASH) Annual Meeting

05 Nov 2024 09:00:00 By Nasdaq GlobeNewswire

Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs

05 Nov 2024 06:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH Annual Meeting

29 Oct 2024 06:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results

06 Aug 2024 06:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics Announces Transition of Chief Financial Officer

15 Jul 2024 06:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD)

26 Jun 2024 06:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease

14 Jun 2024 03:00:00 By Nasdaq GlobeNewswire